Rapamycin Derivatives for Tuberous Sclerosis Tumor Regression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurocutaneous disorders such as Tuberous Sclerosis Complex (TSC) and neurofibromatosis type 1 are inadequate in managing tumor growth and associated symptoms, particularly due to the challenges of managing renal angiomyolipomas, lymphangioleiomyomatosis, and subependymal giant cell astrocytomas.
Innovation Solution
The use of specific rapamycin derivatives, including compounds like ABT578 (zotarolimus), CCI779 (temsirolimus), AP23573, and TAFA-93, which are administered to treat and inhibit the progression of disorders by targeting the underlying genetic mutations, thereby inducing regression of tumors and controlling symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for TSC and NF1, then general symptom management is provided, but tumor growth control is inadequate
Solution Approach 1:
The patent applies parameter changes by using rapamycin derivatives (mTOR inhibitors) that target specific molecular pathways (mTOR signaling) involved in tumor growth. This changes the treatment parameter from general symptom management to targeted molecular inhibition, thereby improving tumor growth control reliability while addressing the inadequacy of conventional treatments
2Reliability
If surgical resection is performed on SEGAs, then tumor removal is achieved, but significant morbidity occurs due to deep location
Solution Approach 1:
The patent replaces the mechanical surgical resection system with a pharmacological system using mTOR inhibitors. Instead of physically removing tumors through surgery (mechanical approach), the treatment uses molecular inhibition to induce tumor regression, thereby achieving tumor removal while avoiding the morbidity associated with deep brain surgery
3Reliability
If rapamycin derivatives are used to treat TSC and NF1, then tumor regression is induced, but treatment specificity and efficacy optimization are needed
Solution Approach 1:
The patent applies local quality by developing specific rapamycin derivatives with optimized molecular structures (formula I compounds) that target mTOR signaling pathways with greater specificity. Different compounds in the series have varying degrees of selectivity for mTOR isoforms, allowing optimization of treatment specificity for different tumor types and patient conditions while maintaining tumor regression efficacy
Data Source
AI summary
Rapamycin derivatives for use in the treatment of neurocutaneous disorders.